文献速递皮肤肿瘤

同步性原发性皮肤黑色素瘤:临床特征、组织学、患者遗传背景与临床结局的描述性研究

Synchronous primary cutaneous melanomas: a descriptive study of their clinical features, histology, genetic background of the patients and clinical outcomes.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2022-08-27

该研究纳入4703例黑色素瘤患者的临床与组织病理数据,分析同步性黑色素瘤的患病率、临床病理特征、胚系突变及生存结局。144例(3.06%)患者同时存在两个或以上原发黑色素瘤;同步性黑色素瘤患者随访期间新发原发黑色素瘤的比例为25.7%,单发黑色素瘤患者为8.6%(P < 0.001)。同步性黑色素瘤患者中胚系CDKN2A突变占10.7%,MC1R基因变异占72%;两组间所有生存结局均无显著差异。

要点

  • 同步性黑色素瘤患病率为3.06%(144/4703),高于既往报告。
  • 同步性黑色素瘤患者随访中新发原发黑色素瘤比例为25.7%,单发黑色素瘤患者为8.6%(P < 0.001)。
  • 同步性黑色素瘤患者胚系CDKN2A突变占10.7%,MC1R变异占72%,但生存结局与单发黑色素瘤无显著差异。

核心结论

  • 同步性黑色素瘤比既往报告的更常见,且与单发黑色素瘤相比在老年患者中更常见。
  • 同步性黑色素瘤患者随访期间新发原发黑色素瘤的风险更高,胚系易感变异频率更高,但这些发现与更差的结局无关。

研究设计与样本

  • 研究纳入4703例黑色素瘤患者的临床与组织病理数据,分析临床、组织学及基因突变状态信息,采用Kaplan-Meier曲线评估生存结局。

主要发现

  • 144例患者(3.06%)同时存在两个或以上原发黑色素瘤。
  • 随访期间,同步性黑色素瘤患者中25.7%发生新发原发黑色素瘤,单发黑色素瘤患者为8.6%(P < 0.001)。
  • 同步性黑色素瘤患者中胚系CDKN2A突变占10.7%,MC1R基因变异占72%。
  • 同步性黑色素瘤患者与单发黑色素瘤患者的所有生存结局均无显著差异。

关键数值与推荐

  • 同步性黑色素瘤患病率为3.06%(144/4703)。
  • 随访中新发原发黑色素瘤比例:同步性黑色素瘤患者25.7% vs 单发黑色素瘤患者8.6%(P < 0.001)。
  • 同步性黑色素瘤患者胚系CDKN2A突变率10.7%,MC1R变异率72%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Around 0.5% of cutaneous melanoma (CM) patients will present with synchronous melanomas when first seen. Moreover, 26-40% of patients with multiple primary melanomas present with synchronous lesions. OBJECTIVES: To assess the prevalence, clinical and histopathological characteristics, germline mutations and outcome in patients with synchronous melanoma. METHODS: Clinical and histopathological data from 4703 melanoma patients were included. Clinical, histological and genetic mutational status information was analysed. Kaplan-Meier curves were used to investigate survival outcomes. RESULTS: A total of 144 patients (3.06%) presented simultaneously with two or more primary melanomas. During follow-up, 25.7% of patients with synchronous melanoma developed a new primary melanoma compared to 8.6% of patients diagnosed with single melanoma (P < 0.001). Germinal CDKN2A mutations were identified in 10.7% of patients with synchronous melanomas and genetic variants in MC1R in 72%. No significant differences in all survival outcomes between patients with synchronous melanomas and single melanomas were found. CONCLUSION: Synchronous melanomas are more frequent than previously reported and are more frequent in older patients compared to single melanomas. Moreover, these patients have a higher risk of developing a new primary melanoma during follow-up and have higher rates of germline susceptibility variants. Nevertheless, these findings were not associated with worse outcomes.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Antúnez-Lay A, Podlipnik S, Carrera C, et al. Synchronous primary cutaneous melanomas: a descriptive study of their clinical features, histology, genetic background of the patients and clinical outcomes. J Eur Acad Dermatol Venereol. 2022. PMID: 35882522. doi:10.1111/jdv.18467

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。